孕19-23周母体心脏功能对子痫前期的预测价值
这项前瞻性观察研究纳入2853例孕19+1至23+3周的孕妇,评估8项母体心脏指标及MAP、UtA-PI、PlGF、sFlt-1对子痫前期(PE)的预测价值。结果显示,调整母体特征和病史后,仅外周血管阻力与后续PE发生显著相关,但将其加入现有筛查模型并未提高预测性能。结论认为母体心脏功能评估有助于理解PE病理生理,但不适用于预测PE。
要点
- 孕19-23周母体心脏功能指标受母体特征和病史显著影响,需标准化后分析。
- 调整混杂因素后,仅外周血管阻力与后续PE发生显著相关。
- 在现有筛查模型中加入外周血管阻力未提高PE预测检出率。
核心结论
- 母体心脏功能评估可提供PE病理生理信息,但对PE预测无实用价值。
研究设计与样本
- 前瞻性观察研究,纳入2853例孕19+1至23+3周孕妇,其中76例(2.7%)发生PE。
- 检测8项母体心脏指标及MAP、UtA-PI、血清PlGF和sFlt-1,采用竞争风险模型评估预测性能。
主要发现
- 后续发生PE的孕妇存在心脏几何形态改变、心肌功能受损和外周血管阻力增加。
- 所有母体心血管指标均受与PE风险增加相关的母体特征和病史因素显著影响。
- 调整母体特征和病史后,仅外周血管阻力受后续PE发生显著影响。
- 外周血管阻力MoM与MAP MoM相关,但与UtA-PI、PlGF或sFlt-1的MoM值均无相关性。
- 在母体特征和病史或联合MAP、UtA-PI、PlGF和sFlt-1的筛查中,加入外周血管阻力未改善PE预测性能。
关键数值与推荐
- 筛查检出率评估基于10%假阳性率。
- 预测目标为<37周分娩PE或任何孕周分娩PE。
临床怎么用
- 孕19-23周常规筛查中,不应将母体心脏功能指标用于PE预测。
- 现有基于母体因素、MAP、UtA-PI、PlGF和sFlt-1的PE筛查模型无需加入外周血管阻力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: First, to examine the factors from maternal characteristics and medical history that affect maternal cardiovascular indices, and, second, to examine the potential value of maternal cardiovascular indices at 19-23 weeks' gestation, on their own and in combination with maternal factors and the established biomarkers of pre-eclampsia (PE), including uterine artery pulsatility index (UtA-PI), mean arterial pressure (MAP), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1), in the prediction of subsequent development of PE. METHODS: This was a prospective observational study in women attending for a routine hospital visit at 19 + 1 to 23 + 3 weeks' gestation. This visit included recording of maternal demographic characteristics and medical history, assessment of maternal E/A ratio, E/e' ratio, myocardial performance index, global longitudinal systolic strain, left ventricular ejection fraction, peripheral vascular resistance, left ventricular cardiac output and left ventricular mass indexed for body surface area, and measurement of MAP, UtA-PI, serum PlGF and serum sFlt-1. The measurements of the eight maternal cardiac indices were standardized to remove the effects of maternal characteristics and elements from the medical history. The competing-risks model was used to estimate the individual patient-specific risks of delivery with PE and determine the detection rate, at a 10% false-positive rate, in screening by a combination of maternal demographic characteristics and medical history with biomarkers. RESULTS: The study population of 2853 pregnancies contained 76 (2.7%) that developed PE. In pregnancies that subsequently developed PE, there was evidence of altered cardiac geometry, impaired myocardial function and increased peripheral vascular resistance. All maternal cardiovascular indices were affected significantly by maternal demographic characteristics and elements of medical history known to be associated with an increased risk for subsequent development of PE. After adjustment for maternal demographic characteristics and medical history, the only cardiovascular index that was affected significantly by subsequent development of PE was peripheral vascular resistance. Peripheral vascular resistance multiples of the median (MoM) was correlated with MAP MoM, which is not surprising because blood pressure is involved in the estimation of both. There were weak correlations between several cardiovascular indices and MAP MoM, but none was correlated with MoM values of UtA-PI, PlGF or sFlt-1. The performance of screening for delivery with PE at < 37 weeks' gestation or delivery with PE at any gestational age in screening by maternal demographic characteristics and medical history or combinations of maternal factors with MAP, UtA-PI, PlGF and sFlt-1 was not improved by the addition of peripheral vascular resistance. CONCLUSION: Assessment of maternal cardiovascular function provides information on the pathophysiology of PE but is not useful in the prediction of PE. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Gibbone E, Wright A, Vallenas Campos R, et al. Maternal cardiac function at 19-23 weeks' gestation in prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2021. PMID: 33294998. doi:10.1002/uog.23568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。